---
schema_version: "secwatch.filing_event.v1"
accession: "0001672688-26-000134"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2026-08-11T20:06:14+00:00"
generated_at: "2026-08-11T20:08:56.204920+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Absci reports positive interim Phase 1 data for ABS-201; completes $100M offering

## Summary
- Positive interim Phase 1 data for ABS-201: well tolerated, half-life ≥65 days, supports 2-3 doses/6 months.
- Completed $100M underwritten offering incl. $40M strategic investment from Eli Lilly; net proceeds $93.6M.
- Cash and securities $201.1M at 6/30/26, up from $125.7M at 3/31/26; runway into H2 2028.
- Q2 2026: revenue $0.3M (vs $0.6M YoY); net loss $33.2M (vs $30.6M YoY).
- ABS-201 endometriosis Phase 2 planned Q4 2026; PHL proof-of-concept data H2 2026.

## SEC filing metadata
- accession: 0001672688-26-000134
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2026-08-11T20:06:14+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000167268826000134/0001672688-26-000134-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000167268826000134/absc-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001672688-26-000134
- JSON: https://secwatch.observer/filing/0001672688-26-000134.json
- Plain text: https://secwatch.observer/filing/0001672688-26-000134.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.